

Workshop

**“Current advances
in the
development of therapies
for neuromuscular disorders
based on
myostatin signalling”**

at the Institute of Myology,

Paris

September 12, 2008

Workshop Program

Reception of participants: 9:00-9:30

in the hall of the Institute of Myology

Morning session : 9:30 – 12:30

Presentations of current work and future projects. Introductions not required.

Talks : 10 min, discussions : 5 min,

Thomas Voit (Institut de Myologie, Paris)

Welcoming

Objectives of the meeting

Helge Amthor (Institut de Myologie, Paris)

Current and old problems in myostatin research.

See Jin-Lee (Johns-Hopkins University, Baltimore, USA)

Myostatin: A Molecular Rheostat For Muscle Mass.

Terence Partridge (Children's National Medical Center, Washington, USA)

Critical view on cellular basis of excessive muscle growth in absence of myostatin.

George Dickson (School of Biological Sciences, Royal Holloway, UK)

Myostatin inhibition by propeptide and antisense gene therapy.

Keith Forster (School of Biological Sciences, Royal Holloway, UK)

Effects of AAV-mediated myostatin propeptide expression in normal and mdx mice

Coffee break: 11:00-11:15

Julie Dumonceaux (Institut de Myologie, Paris)

Current strategies of AAV mediated myostatin blockade in mouse models.

Luis Garcia (Institut de Myologie, Paris)

Myostatin blockade in normal and muscular dystrophy dogs.

Combination of AAV mediated myostatin blockade and dystrophin rescue by exon skipping in animal models for Duchenne muscular dystrophy.

Antony Otto (School Biological Sciences, University of Reading, UK)

Myostatin and Wnt signalling networks during satellite cell activation.

Etienne Mouisel (Institut de Myologie, Paris)

Problems of exercise capacity and force generation in absence of myostatin.

Innervation dependent effect of myostatin blockade.

Christophe Hourdé (Institut de Myologie, Paris)

Consequences on muscle metabolism in absence of myostatin.

Lunch break: buffet (12:30 – 13:30)

Afternoon session:

▶ Part one (13:30 – 14:15)

Continuation of project presentations

Kristina Jülich (Charité University Medicine, Berlin)

The influence of myostatin on rhabdomyosarcoma growth and differentiation

Ketan Patel (School Biological Sciences, University of Reading, UK)

The effects of high-fat diet and calorie-restricted diet in absence of myostatin.

Markus Schülke (Charité University Medicine, Berlin)

Current technical advances in myostatin dosage, generation of recombinant myostatin and anti-myostatin antibodies.

▶ Part two (14:15 – 14:45)

Some perspectives in myostatin research:

Talks 10 min, discussion 5 min,

Terence Partridge (Children's National Medical Center, Washington, USA)

Setting up models for analysing the effects of myostatin on muscle fibres in tissue culture

Luis Garcia (Institut de Myologie, Paris)

Novel hypothesis: Adipose metaplasia in muscular dystrophy and possible involvement of myostatin.

▶ Part three (14:45 – 15:30)

General discussion of problems identified during the morning session.

Future strategies to overcome pitfalls. How to advance therapy development and preclinical work.

▶ Part four (15:30 – 16:15)

Discussion in small groups with the aim to synchronise current work around the coffee bar.

▶ Part five (16:15 – 17:00)

How to take things forward.

- Identify common projects
- How to coordinate future projects
- Outline common grant proposals, identify funding agencies and deadlines

17:00 Closing remarks

19:00 Diner (*location will be confirm later on*)

